On Wednesday November 2, 2011, it was broadcasted today that Biomoda, Inc. (OTC:BMOD) has filed an application for a new U.S. Patent that process the usage of fluorescent microscopy in order to optimize the CyPath(R) diagnostic analysis for lung cancer.
Biomoda, Inc. is a Cancer diagnostics company, primarily focused on the development of optimized, inexpensive and noninvasive tests for the early detection of cancer.
The porphyrin-based CyPath(R) analysis combines with cancer cells thereby enabling them to fluoresce under particular frequencies of light. CyPath(R) was recognized as a noteworthy biomarker for lung cancer by the pilot clinical study concluded in March 2011.
At present, Biomoda possess four U.S. patents and foreign patent rights in Europe, Canada, Japan, Mexico and Australia.
Maria Zannes, Biomoda CEO acknowledged that the thorough study of optimization in order to improve the sensitivity and specificity of the analysis has resulted in the respective invention of technology the intellectual property being Biomoda’s prime asset the company will strive to upsize it through more invention of similar type.
Shares of BMOD soared 36.36% to $0.015 with most of gains coming the final two hours with more than 61K shares traded hands.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial advisor.